Syros Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Syros Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2015 to Q2 2024.
  • Syros Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $1.8M, a 35.9% decline year-over-year.
  • Syros Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $8.88M, a 21.5% decline year-over-year.
  • Syros Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $10.4M, a 8.55% decline from 2022.
  • Syros Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11.4M, a 10.2% increase from 2021.
  • Syros Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $10.4M, a 5.35% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $8.88M $1.8M -$1.01M -35.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $9.89M $2.1M -$542K -20.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $10.4M $1.72M -$1.18M -40.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 $11.6M $3.26M +$300K +10.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $11.3M $2.81M +$125K +4.65% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $11.2M $2.65M -$218K -7.61% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $11.4M $2.9M +$28K +0.97% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 $11.4M $2.96M +$859K +41% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $10.5M $2.69M +$236K +9.62% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $10.3M $2.86M -$67K -2.29% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $10.4M $2.88M -$155K -5.12% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-02
Q3 2021 $10.5M $2.1M -$627K -23% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $11.1M $2.45M -$274K -10% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $11.4M $2.93M +$471K +19.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $10.9M $3.03M -$185K -5.75% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-02
Q3 2020 $11.1M $2.72M +$334K +14% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $10.8M $2.73M +$371K +15.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $10.4M $2.46M +$580K +30.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $9.84M $3.22M +$1.58M +96.9% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-15
Q3 2019 $8.26M $2.39M +$852K +55.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $7.41M $2.36M +$612K +35.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $6.79M $1.88M +$183K +10.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $6.61M $1.63M +$362K +28.5% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-04
Q3 2018 $6.25M $1.54M +$429K +38.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $5.82M $1.74M +$588K +50.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $5.23M $1.7M +$812K +91.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-01
Q4 2017 $4.42M $1.27M +$541K +74.1% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-05
Q3 2017 $3.88M $1.11M -$586K -34.6% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 $4.46M $1.16M +$8K +0.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $4.46M $884K +$222K +33.5% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 $4.23M $730K Oct 1, 2016 Dec 31, 2016 10-K 2019-03-07
Q3 2016 $1.69M +$433K +34.3% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $1.15M +$535K +87.3% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $662K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q3 2015 $1.26M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 $613K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.